Sobi Reaches $1.5 Billion Definitive Agreement with Arthrosi Therapeutics to Acquire Gout Treatment

Pharmaceutical Executive December 15, 2025
Nicholas Jacobus

Key Takeaways

• Sobi’s acquisition of Arthrosi Therapeutics for $1.5 billion includes pozdeutinurad, a promising gout treatment asset.
• Pozdeutinurad, a URAT1 inhibitor, shows efficacy in reducing serum uric acid and dissolving tophi in Phase II trials.
• Phase III trials, REDUCE 1 and REDUCE 2, are fully enrolled, with pivotal data expected in 2026.
• The acquisition involves a $950 million upfront payment and up to $550 million in milestone payments, funded primarily through debt.

Sobi’s $1.5 billion acquisition of Arthrosi Therapeutics positions the company for long-term growth and strengthens its gout treatment portfolio.

Sobi has announced an agreement to acquire Arthrosi Therapeutics for $1.5 billion, which will expand the company’s gout pipeline with pozdeutinurad (AR882), Arthrosi’s leading gout treatment asset.¹

Today's Sponsors

Today's Sponsor